“…This difference may be due to the local effects on inflammatory cells, mainly on mast cells, exerted by topical steroids, which act directly on resident inflammatory cells. Noteworthy, it was previously reported that deflazacort, a systemic steroid, reduces clinical and inflammatory events only during the late phase occurring after conjunctival challenge; but it is able to reduce ICAM‐1 expression on epithelial cells also during the early phase [ 22].…”